This study is designed to assess the repeatability of organ-specific quantitation of
radiotracer uptake following Positron Emission Tomography/Computed Tomography (PET/CT)
imaging of AT- 01 in subjects with amyloid light chain (AL) or amyloid transthyretin (ATTR)
This is a multicenter, open label, single arm study in subjects with amyloid light chain (AL)
or amyloid transthyretin (ATTR) systemic amyloidosis with visceral amyloid deposits. This
study consists of a screening period of up to 30 days; two one-day treatment periods (Day 1
and Week 6); a safety follow-up 24-48 hours after the second administration of 124I AT-01,
and a safety follow-up visit 28 days after the second administration of 124I-AT-01.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.